We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 6,637 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/11/2020 21:08 | They are aiming to gain enough data to allow commercial talks to begin but theoretically they could license it out now, although I doubt they’d achieve the sums of money they have in mind at this stage! The patent needs finalising and this could be the only reason we ain't getting the finer detail passed to investors that we’d normally see, they state the patio likely to be given in full before year end. The did always plan to be in the clinic for 2020 and I’d like to think this is still on track but obviously the delays and difficulties seen with the pandemic may dictate differently. Most investors know these things take time, sadly the traders want the deals before it’s ready. | featherby81 | |
13/11/2020 21:06 | Longer term the best company I have ever seen is OPTI. I have no idea when the market will realise their absolutely massive potential but it surely will at some point. Not really a Pharma but their products have been subject to clinical trials and have fantastic scientific evidence backing them. | nobbygnome | |
13/11/2020 21:05 | Short term STX is the best buy IMHO. A US licensing deal for their approved product gunning for a $billion market is imminent. I am expecting a good 40% upside when this is announced although of course it does depend on the terms to some degree. No investment advice intended.... | nobbygnome | |
13/11/2020 21:01 | Thank you Nobby. First time I’ve looked seriously at a Pharma given I liked the sound of their product . Also appreciated feather’s response .What in your view are the alternatives I could consider and why? Cheers. | richjj | |
13/11/2020 20:53 | >> Rich Zero chance of a takeover here, Pharma doesn't gamble on unproven technologies! | nobbygnome | |
13/11/2020 20:51 | >> Barrie No, I was otherwise engaged trading some serious companies not this dross! You all know my views about N4P so I won't bother to articulate them again. | nobbygnome | |
13/11/2020 20:49 | Thank you feather. Are we talking about possible clinical trials next year in your view if all things come together as planned ? Additionally as this is a relatively small and knowledgable company is there a real risk that they would be taken over by a larger Pharmaceutical company ? | richjj | |
13/11/2020 20:07 | Hi RichJJ Only my opinion but I’d say we’ll definitely get a decent breakdown of the results from Nigel on the phase 3 covid work, it seems N4 have joined a growing trend of investor updates after a company releases news’s (on AIM. We’ve got a little way to go until we are safely out of the woods on the coronavirus works, they assume it’ll generate the antibodies and provide a positive outcome but as with every experiment, its not a dead certain outcome until proved. It’s worth noting the covid study is also being used as a comparative study against other familiar plasmids which is exactly what’s needed to complete the data package. We are looking to gain trust and understanding amongst developers looking to improve on their existing delivery systems, they need to be comfortable N4 know their product and have an understanding on how it can be formulated to fulfil their requirements. I’m a long term holder and feel there’s significant potential as each stage is proven up, if and when we start clinical (human) trials we won’t be hovering around this £10m MCAP valuation. | featherby81 | |
13/11/2020 17:19 | New to N4P but invested as see the potential . When do you think further presentations will follow from the company and how far do you feel the product will develop this year given the possible recent COVID vaccine intentions going into early next year. ?Additionally how far do you see the share price moving in this regard ? Thanks for your insights in advance. | richjj | |
13/11/2020 11:34 | If vaccines are the now, delivery systems are the future:))) | ch1rp | |
12/11/2020 17:19 | Nobbygnome Tell me you took a punt on these this morning, nobby!! | barrie16 | |
12/11/2020 15:10 | Yep, all good in the hood. | jibba jabber | |
12/11/2020 14:35 | Should be pushing up to 8p soon | julianw2 | |
12/11/2020 09:44 | Huge rise expectations here:))) | ch1rp | |
11/11/2020 07:39 | "Please don't compare me to Stig. He is foul mouthed and obnoxious." Can't argue with that :-) but he makes us a shed load of dosh. In the Stig we Trust. | hodhasharon | |
11/11/2020 07:38 | Isn't anyone else here seriously excited?Nuvec is quietly working it's way successfully through its target tests.Who wants to be jabbed year upon year in defence against cancer or Covid when you could simply take a pill?GET REAL PEEPS!!! | ch1rp | |
09/11/2020 14:55 | Still an interesting prospect. In for another 70k(shares).Will be huge if proven successful Novec IMHO | pwal | |
09/11/2020 14:40 | Pre COVID this is about 4p Avct about 25p Then theres sng , that’s a big loss Don’t panic sell tho because even if they go that low, their still the same companies Doing the same work. | glenglad | |
09/11/2020 14:36 | You should have waited vol, all COVID related shares are collapsing and probably won’t stop untill this vacine is being used. | glenglad | |
09/11/2020 13:54 | Got some more for 5.38p | volsung |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions